Summary. In order to determine the role of glucagon in futile or substrate cycling in diabetes, we measured tracer determined glucose kinetics during a combined infusion of 2-3H -glucose (total glucose production) and 6-3H-glucose (glucose production) in six alloxan-diabetic dogs. The animals received either a 420rain infusion of (1) somatostatin alone (0.3 Ixg. kg -1 -m in-l), (2) somatostatin with insulin replacement (1001xU.kg-l-min -1) or (3) glucagon (6ng.kg -1. min -1) together with somatostatin and transient insulin replacement. When somatostatin was given alone, plasma glucagon (p <0.004) and insulin (p <0.0001) were suppressed. Glucose production and disappearance and plasma glucose concentrations fell (p < 0.0001), but the metabolic clearance of glucose did not change significantly. In the basal state, futile cycling comprised 29_+ 4%, 33 __+ 4% and 33 _+ 3% of total glucose production in the three goups of studies, which is high compared to normal dogs. The absolute rate of futile cycling fell slightly but significantly from 10.0+1.7 to 8.3+ 1.7 ~tmol. kg--lmin-1 (p < 0.0008). When insulin replacement was given during somatostatin infusion to correct for the small somatostatin-induced insulin suppression, there were similar changes in plasma glucagon, glucose concentrations and glucose kinetics as seen during the infusion of somatostatin alone. Futile cycling decreased to a slightly greater extent from 12.8+2.8 to 9.5+l.7~tmol.kg-l-min. -1 (p<0.02). When glucagon was infused together with somatostatin and insulin replacement, plasma glucagon (p < 0.0002) increased and plasma glucose levels rose (p < 0.001) due to a transient increase in glucose production. Metabolic clearance of glucose did not change significantly. There was a marked increase in futile cycling from 12.2+1.7 to 21.7_+1.7 ~tmol. kg -1. min -1 (t7 < 0.0001) in response to exogenous glucagon excess. There was a slight (p < 0.01) drop in free fatty acid levels with somatostatin. Free fatty acid levels nearly doubled (t7 < 0.025) with the infusion of glucagon together with somatostatin. In conclusion, (a) futile cycling was increased in alloxan-diabetic dogs; (b) glucagon suppression can suppress futile cycling only if total insulin deficiency is prevented; and (3) hyperglucagonaemia increases futile cycling, and this effect is more pronounced during insulin deficiency.
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Glucagon suppression by somatostatin has been proven to be effective in decreasing plasma glucose levels in diabetic patients [1] [2] [3] . More recently, we have shown that glucagon suppression is effective in decreasing hepatic glucose production in alloxan-diabetic, but not depancreatized, insulin-deprived dogs [4] , indicating that small amounts of insulin are required for the reversal of the glucagon-induced catabolic cascade [5] .
In the normal or diabetic liver new glucose is produced by both glycogenolysis and gluconeogenesis. However, a portion of glucose taken up by the liver is not polymerized to glycogen or oxidized; rather, it reenters the circulation after phosphorylation followed by rapid dephosphorylafion. These are two "non-equilibrium" reactions which are catalyzed by two separate enzymes [6] . This constitutes a futile or substrate cycle which has been termed the glucose cycle [7] . Both the substrate and product are the same metabolite, and each turn of the cycle uses up a high-energy phosphate bond. There are two other futile cycles: the fructose-6-phosphate cycle and the phosphoenolpyruvate cycle. Futile cycling is a separate consideration from recycling of radioactive 3-carbon fragments through the Cori Cycle.
In normal dogs, futile or substrate cycling comprises 13-20% of the glucose output from the liver [8] [9] [10] [11] . The activity of the glucose cycle is increased in normal animals after 45 min of selective insulin deficiency [11] , in diabetic dogs [12] and in man [13] , contributing to the overall increase in glucose production in these situa-tions. The increase in futile cycling of glucose could be due to insulin deficiency and/or excess of counterregulatory hormones in diabetes. It has been shown in normal animals that both glucagon [9, 11] and cortisol [9, 12] can increase futile cycling. The specific role of glucagon in regulating futile cycling in diabetes has not been established.
We wished to establish the role of glucagon in increased futile cycling in diabetes. As glucagon suppression decreased hepatic glucose production in alloxandiabetic dogs [4] , we also wished to see whether this was due, at least in part, to a decrease in futile cycling. We therefore examined the effects of combined insulin and glucagon deficiency, selective glucagon deficiency and selective glucagon excess.
Materials and methods

Preparation of experimental animals
Diabetes was induced in six mongrel dogs weighing 18-22 kg using 60 mg/kg alloxan (Sigma, St. Louis, Mo, USA). At least 10 days before the commencement of the first study the animals underwent surgery to provide portal, jugular and saphenous vein cannulae [14] . The animals were treated with regular and Neutral Protamine Hagendornf (NPH) porcine insulin (Connaught Laboratories, WiUowdale, Ontario, Canada) adjusted daily according to the degree of glycosuria [13, 15] . We have shown in previous studies that with such insulin therapy, the animals do not develop insulin antibodies for at least 2 months [16] . Each animal maintained their weight within ___ 3 kg, and they remained afebrile, healthy and were eating well throughout the period that they were being studied.
Experimental design
Two days prior to each experiment NPH insulin was stopped. The last dose of regular insulin was given at 16.00 hours the day before each study. Food was withdrawn 18 h before each study. The animals were trained to lie quietly during each experiment. The hematocrit was assessed before each study; if the hematocrit fell below 35%, the study was abandoned.
Three experimental protocols were carded out on separate days, in which the dogs received (1) 3 h equilibrium and control period followed by a 7.5-h infusion of somatostatin (0.3 Ixg-kg -1. rain -1) and a 1-h recovery period; (2) an intraportai insulin (100 IxU. kg -1. min -1) infusion during the somatostatin infusion in order to maintain plasma insulin at usual basal levels for these diabetic animals; or (3) intraportal glucagon (6 ng. kg -1. min -1) and insulin (100 ~tU. kg -1. rain -1) given together with somatostatin (0.3 ~tg.kg -1 -min -1) for 3 h, after which the insulin infusion was stopped and glucagon and somatostatin were continued for a further 3 h in five animals. The three sets of studies were carded out in random order.
Cyclic somatostatin (Ayerst Laboratories, Montreal, Quebec, Canada) was dissolved immediately before use in normal saline containing 0.2% bovine serum albumin (fraction V, Armour Pharmaceuticals, Chicago, Ill, USA). Glucagon (Eli Lilly and Company Limited, Toronto, Ontario, Canada) was diluted in normal saline containing trasylol (Bayer AG, Leverkusen, FRG, KIU/dl saline) and the dogs' own plasma (2 ml/dl saline adjusted to pH 8.5 with bisodium hydroxide). Regular porcine insulin (Connaught Laboratories, Willowdale, Ontario, Canada) was diluted in normal saline containing the dogs' own plasma (2 ml/dl saline adjusted to pH 8.5 with bisodium hydroxide).
Tracer methods
A primed constant infusion of a combination of 2-3H-glucose (5 mCi/ ml, New England Nuclear Canada, Lachine, Quebec, Canada) and 6-3H-glucose (5 mCi/ml, New England Nuclear Canada) was given at a constant rate (0.096 ml/min) throughout the study. A prinaing dose equivalent to the amount infused in 150min was given at the beginning of each experiment.
Using 2-H-glucose as tracer, the sum of glucose produced by glycogenolysis, gluconeogenesis and futile cycling (total glucose output or appearance) can be measured. Glucose turnover measured with 6-3H-glucose closely approximates glucose production (Ra), because the sixth carbon is lost after glucose is metabolized to the point that it can no longer enter any of the futile cycles; it thus measures only glucose derived from glycogenolysis and gluconeogenesis. As a consequence, futile cycling of glucse can be calculated by subtracting glucose production measured by 6-3H-glucose from that measured using 2-3H-glucose.
The steady and non-steady state tracer infusion methods for calculating the rates of appearance (R~) and disappearance (R0) of endogenous glucose using a one compartment model have been described and validated in vivo [17] [18] [19] . It has been shown that this method does have to be modified during hyperinsulinaenlic, englycaemic clamps where glucose uptake is maximally increased [20] , but conventional calculations appear valid under conditions such as those in the present study. Glucose clearance was calculated as Rd/C, where C equals glucose concentration, but can also be directly derived from original tracer data in the same way as Ra if the concentration of labelled glucose is measured rather than specific activity [21] , and thus is a reliable measurement. Although the metabolic appearance of glucose does vary with plasma glucose concentrations, it is still clearly related to insulin action and thus is a useful parameter.
Laboratory methods
Blood samples for measurements of labelled and unlabelled glucose and immunoreactive insulin (IRI) concentrations were collected in dry heparinized tubes containing sodium fluoride as preservative. After centrifugation, plasma for determination of specific activity of glucose was deproteinized in equal volumes of 5% zinc sulphate and 0.3 N barium hydroxide. A 1-ml aliquot of the superuatant was evaporated to dryness in order to eliminate any tritium present as 3 H20. The residue was redissolved in 1 ml water and counted in Aquasol II (New England Nuclear Corporation, Boston, Mass, USA) by liquid scintillation spectrometry to obtain total specific activity (2-3H-glucose plus 6-3H-glucose). A second aliquot of plasma was then subjected to a procedure to isolate the radioactivity originating from the 6-3H-gl ucose [22] . The glucose from the sample, together with glucose carrier, was oxidized with periodic acid and the glucose molecule was thus broken into 5 formic acid molecules and 1 formaldehyde molecule. As the formaldehyde was formed from the 6 carbon atom of glucose, it contained all the tritium from the 6-3H-glucose. The formaldehyde was precipitated with sodium arsenite and dimedone into an insoluable complex. After filtering, drying and weighing, the wafer was placed in acquasol II solution and counted by liquid scintillation spectrometry to obtain 6-3H-glucose specific activity. The 2-3H-glucose specific activity was calculated by subtracting this value from that for total specific activity. For each experiment an aliquot of the infused tracer infusion was prepared and treated in the same way as plasma samples, and counted in Aquasol II by liquid scintillation spectrometry. That portion of glucose production accountable by futile cycling was calculated by subtracting the rate of appearance of glucose measured using 6-3H-glucose as tracer from that measured using 2-3H-glucose.
The glucose-oxidase method was used for determination of plasma glucose levels (Glucose Auto Analyser, Beckman Instruments Incorporated, Fullerton, Calif, USA). Plasma IRI was determined by radioimmunoassay using an anti-beef insulin anti-serum (supplied through the courtesy of Dr. Peter Wright, Indianapolis, Ind, USA), a purified dog insulin standard and porcine insulin labelled with 1 lz5 . Dextran-coated charcoal was used for the separation of free from bound hormones [23] . The method was modified by double-diluting the antibody, in order that the assay be sensitive to insulin concentrations as low as 4 ~tU/ml. It was possible to measure plasma insulin accurately, as the animals had been treated with porcine insulin, which does not induce antibody formation for at least 2 months [16] . For the determination of plasma immunoreactive glucagon (IRG) and plasma free fatty acids (FFA), 4 ml blood was added to chilled tubes, each containing 0.2 ml EDTA 26 ml/dl and 0.2 ml TRASYLOL (2000 KIU, FBA Pharmaceuticals, New York, NY, USA). Plasma glucagon was determined by radioimmunoassay [24] using 30k anti-serum (supplied by Dr. R.H.Unger, Dallas, TX, USA), which reacts with the C-terminal moity of 35~176 and I~SI-labelled glucagon (Novo Research Institute). Plasma free fatty acid levels were determined by a radiochemical assay [251.
Statistical analysis
Values were presented at a mean___ SEM, Statistical analysis was performed using the SAS R (statistical analysis system, SAS Institute Inc., Carey, N.C., USA). When responses to a treatment were assessed, we used a two-way analysis of variance. When individual points were compared within a study, a paired Student's t-test was used. Significance was presumed at p < 0.05. 
Results
Hormonal responses
As shown in Figure 1 , somatostatin with (F= 5.49, p < 0.02) or without (F=9.10, p <0.004) insulin replacement induced a sustained decrease in plasma glucagon (IRG) to levels close to the lower limits of sensitivity of the glucagon assay in each experiment. After the infusions were stopped, plasma IRG increased promptly. This allowed us to assess the effects of endogenous hyperglucagonaemia on glucose turnover and futile cycling. With the infusion of glucagon together with somatostatin and insulin replacement, IRG rose rapidly (F = 16.7, p < 0.0002) and remained elevated. When the insulin infusion was stopped, IRG did not rise further.
During the infusion of somatostatin alone (Table 1) , the already decreased levels of plasma insulin (IRI) fell further (F = 34.95, p < 0.0001). When insulin (100 ~tU-kg-a-min -1) was given together with somatostatin, there was still a slight drop (p < 0.005) in IRI initially, but between 150 and 450 min IRI levels were not different from basal. After the infusions were stopped, plasma insulin values rebounded to suprabasal levels (F=38.83, p<0.0001 after somatostatin alone; F = 14.63, p<0.0004, somatostatin+insulin), indicating that some residual B-cell function was preserved in the alloxan-diabetic dogs. Since these levels were compara- lqig.4. Values for rates of true glucose production or appearance (R~, measured using 6-H-glucose as tracer), glucose disappearance (Rd) and futile cycling (FC) in response to the infusion of (1) somatostatin alone (O------~), (2) somatostatin+insulin replacement ( 9 O) and (3) glucagon + somatostatin + insulin replacement (,--O). Insulin was withdrawn in the third study at 180 min. The values plotted represent the mid-point of each time period over which R~, Rd and FC were measured and are presented as mean _ SEM ble to basal levels in normal dogs, we could determine the effects of endogenous hyperglucagonaemia in the presence of normal basal insulin levels. When glucagon was given with somatostatin and insulin replacement, there was a slight decrease in plasma IRI. After the insulin infusion was stopped, there was a further decrease in IRI plasma concentrations.
Plasma glucose and free fatty acid levels
During the infusion of somatostatin alone (Fig. 2) , plasma glucose levels fell gradually from 15.8-+1.1 to 9.46 _+ 0.7 rnmol/1 (F=115.65, p<0.0001), then returned almost to basal after the end of the somatostatin infusion. When insulin was given to provide concentrations comparable to those usually seen in the basal state in alloxan-diabetic dogs, the somatostatin-induced decrease in plasma glucose from 15.8+2.5 to 9.1+ 1.6 mmol/1 (F = 68.73, p < .0001) was almost identical to that seen when somatostatin was given without insulin replacement. After the infusion there was a similar restoration of plasma glucose toward basal values. During the infusion of glucagon together with somatostatin and insulin replacement, glucose rose significantly (F = 42.55, p < 0.0001) but did not rise further after insulin was withdrawn.
During the infusion of somatostatin alone (Fig. 3) , free fatty acid (FFA) levels fell from 1589 + 214 to a nadir of 985 +_157 ~tmol/1 (F=11.4, p<0.001). Plasma FFA levels did not rise after the end of the somatostatin infusion. When insulin replacement was given together with somatostatin, the drop in FFA (F = 4.44, p < 0.05) was somewhat smaller than with infusion of somatostatin alone. During the infusion of glucagon together with somatostatin and insulin replacement, basal FFA levels were 1144-+171 ~tmol/1 and rose continuously both during and after insulin withdrawal, reaching a final value of 1978 + 228 p.mol/1, which was significantly higher than basal (p < 0.025).
Changes in tracer-determined glucose kinetics and futile cycling
During the infusion of somatostatin alone (Fig. 4, upper  panel) , hepatic glucose production (Ra) fell from 22.8+1.7 to ll.l+0.6~tmol-kg-l-min -1 (F=85.56, p < 0.0001), then rose to near basal lavels following the end of the somatostatin infusion. When insulin replacement was given during the somatostatin infusion, there was an equivalent decrease in Ra from 23.4_+3.3 to 12.2_+l.7p.mol.kg-l.min -1 (F=61.12, p<0.0001). When glucagon was given together with somatostatin and insulin replacement, there was a prompt initial rise in Ra from 23.9_+1.7 to 38.4_+6.1~tmol.kg-l.min -1 (p <0.05 at 60 and 90 min), and a gradual decline to 26.7 _+ 1.7 ixmol 9 kg. -amin-1. When the insulin infusion was stopped, Ra remained stable.
During the infusion of somatostatin alone (Fig.4 , middle panel), the rate of disappearance of glucose (Ra) fell from 22.8+1.7 to 12.8+0.6~tmol.kg--lmin -1 (F=46.98, p <0.0001) but did not rise again significantly after the infusion. When insulin replacement was given with somatostatin, Ra fell from 23.4_+3.3 to 13.9+1.7p~mol-kg.-lmin -~ (F=25.25, p<0.0001). During the infusion of glucagon with somatostatin and insulin replacement, Ra rose significantly (F--9.27, p < 0.0035) but returned to basal by 150 min. When insulin was stopped, Ra remained near basal values. The metabolic clearance of glucose did not change significantly in any of the three sets of experiments.
There was a marginal decrease in absolute values for futile cycling from (FC) 10.0+1.7 to 8.3_+ 1.7 ~tmol-kg. -lmin-1 (Table 2 ) during the infusion of somatostatin alone (F = 7.32, p < 0.008); however, when somatostatin was given with insulin replacement the decrease in FC was slightly greater, falling from 12.8 +_ 2.8 to 9.5 +__ 1.7 [xmol. kg. -lmin-1 (F---5.36, p < 0.02). Figure 5 shows mean values for total glucose appearance calculated using 2JH-glucose (~), glucose production calculated using 6-3H-glucose (~) and the difference between these values which measures futile cycling (FC) (~. Percentages refer to the percentage of total glucose appearance accounted for by futile cycling. Top panel gives basal rates for total glucose appearance, glucose production R~ and FC; overall responses to the infusion of somatostatin alone (rates between 120 and 450 min were averaged to obtain the overall response); and rates during the recovery period (rates between 450 and 540 min were averaged). Values are presented as mean + SEM. Middle panel gives basal rates for total glucose appearance, glucose production and FC; overall responses to the infusion of somatostatin+insulin replacement (rates between 120 and 450min were averaged to obtain the overall response); and rates during the recovery period (rates between 450 and 540 rain were averaged). Values are presented as mean + SEM. Bottom panel gives basal rates for total glucose appearance, glucose production and FC, overall response to the infusion of glucagon + somatostatin + insulin replacement (rates between 120 and 150min were averaged). Values are presented as mean ___ SEM When glucagon was given together with somatostatin and insulin replacement, FC rose from 12.2_+1.7 to 21.7 +__ 1.7 Ixmol. kg. -lmin-I (F = 27.1, p < 0.0001). There was no further increase in FC when insulin infusion was stopped, but rather a decrease toward basal by the end of the infusion. Figure 5 summarizes the overall changes in total glucose appearance (measured using 2-3H-glucose), glucose production (Ra, measured using 6-3H-glucose) and FC during the three experimental studies. In these diabetic animals, basal levels of glucose production were higher than seen in normal animals. In addition, the proportion of glucose production accounted for by FC was high, comprising between 29 + 4% and 33 + 4% of total glucose appearance. During the infusion of somatostatin alone (Fig. 5, upper panel) , both total glucose appearance (p < 0.01) and Ra (p < 0.005) decreased, but the absolute rate of FC was unaltered. Thus, FC during glucagon suppression comprised 42_+ 4% of total glucose appearance (p < 0.02 compared to basal). During the recovery period in which there was hyperglucagonaemia with normal insulin levels, total glucose appearance (t7 < 0.025) and Ra (p < 0.05) increased again. Futile cycling also increased, but remained at 42 + 4% of total glucose appearance (p < 0.0001 compared to basal). With insulin replacement during somatostatin infusion (Fig. 5, middle panel) , total glucose appearance (p < 0.01), Ra (p < 0.005) and FC decreased. FC comprised 41 _+ 3% of total glucose production, but this increase was not significant; it was, however, significant in the recovery period (43 + 4%, p < 0.05 compared to basal). When glucagon was given together with somatostatin and insulin (Fig. 5, lower panel) , providing a selective increase in glucagon, total glucose appearance (p < 0.025) and FC (p < 0.01) increased, but final Ra values did not change significantly. FC comprised 43 _+ 2% total glucose production (p < 0.05 compared to basal).
Discussion
We have examined the role of glucagon in the control of futile cycling in alloxanized dogs, an experimental model for diabetes, by assessing the effects of (1) combined insulin and glucagon deficiency, (2) glucagon deficiency with insulin replacement to prevent the somatostatin-induced decrease in plasma insulin and (3) glucagon excess, both (a) exogenous with hypoinsulinaemia and (b) endogenous accompanied by normoinsulinaemia. Combined glucagon and insulin suppression resulted in a decrease in glucose production (Ra) but only a slight decrease in futile cycling (FC). When basal insulin levels were maintained during somatostatin infusion, glucagon suppression resulted in a decrease in both P~ and FC. Glucagon excess resulted in an increase in both Ra and FC, and this was true whether the increase in plasma glucagon concentration was due to glucagon infusion or to endogenous glucagon release. The increase was smaller when normal basal insulin levels were present such as was seen during endogenous hyperglucagonaemia, although the glucagon levels achieved were perhaps slightly lower.
It is well recognized that glucagon and other counterregulatory hormones such as epinephrine and cortisol act synergistically to increase hepatic glucose production, particularly in diabetes [26] , and it is possible that elevated levels of the catecholamines and cortisol in our alloxan-diabetic dogs could have interacted with glucagon and been responsible for part of the observed effects in our studies. We have recently carried out a study in alloxan-diabetic dogs in which we showed no significant difference in basal levels of these hormones from basal levels observed in normal control dogs [27] . Basal plasma glucose levels were virtually identical to those in our present study.
It is also well known that somatostatin suppresses growth hormone release, and it has been suggested [28] that this could enhance glucose disposal, counterbalancing the effects of insulin suppression. However, it has been shown [29] that when somatostatin was given during a combined insulin and glucagon clamp to maintain normal basal levels of these hormones, glucose turnover did not change significantly, indicating that the main glucoregulatory effects of somatostatin are through alterations in pancreatic hormone release. Also, a recent study [30] failed to show that somatostatin per se could increase insulin-stimulated glucose uptake.
In the basal state in our alloxan-diabetic dogs, between 29% and 33% of total glucose appearance was attributable to futile cycling. This is considerably more than the 13%-20% reported in normal dogs [8] [9] [10] [11] . In normal man [31] , futile cycling was approximately 10% of total glucose appearance. In Type 2 (non-insulin-dependent) diabetes [13] , futile cycling was increased in the basal state and rose further during glucose infusion.
Futile cycling decreased slightly during bihormonal glucagon and insulin deficiency; when insulin was given together with somatostatin to restore insulin levels to the usual basal levels for these diabetic animals, futile cycling decreased to a somewhat greater extent. In order to restore futile cycling to normal values in diabetes, it may be essential to restore normoinsulinaemia as well as suppress plasma glucagon levels.
Not only did futile cycling increase during both endogenous and exogenous glucagon excess, but the proportion of total glucose production that was attributible to futile cycling also rose, suggesting that futile cycling is not a constant fraction of hepatic glucose production. One other study [32] suggests that futile cycling can change independently of glucose production, for it was shown that basal glucose production is increased by only 18% in acromegalic patients, as opposed to normal man, whereas futile cycling is increased by 76%. However, when insulin infusion was stopped during infusion of glucagon and somatostatin, futile cycling did not increase further, suggesting that glucagon excess may be a greater determinant of the extent of futile cycling in diabetes than is the degree of insulin deficiency.
In normal dogs [10] , when glucagon was infused at the same rate as in the present study and insulin was suppressed by somatostatin, futile cycling rose; by the end of the 75-min infusion period it accounted for 40% of the total glucose production. In normal dogs without insulin suppression, infusion of glucagon at 10 times the infusion rate as in the present study [9] resulted in an increase in futile cycling which was similar to that seen in our study, even though we used a much lower infusion rate. Also in the present study, the glucagon-induced increase in futile cycling was greater when hyperglucagonaemia was accompanied by hypoinsulinaemia. Thus, glucagon appears to be more effective in increasing futile cycling during hypoinsulinaemia. When normal dogs were given methylprednisolone for 3 days prior to the glucagon infusion [9] , basal plasma glucose concentrations and Ra were both elevated in the basal state. Thus, they were comparable in some respects to our alloxan-diabetic animals. However, they had an even higher basal rate of futile cycling than our alloxandiabetic animals. Futile cycling and total glucose production rose enormously when glucagon was given to these methylprednisolone-treated dogs, suggesting a synergistic effect of methylprednisolone and glucagon.
It is difficult to fully characterize the underlying biochemical abnormalities responsible for the increase in futile cycling in our alloxan-diabetic dogs, and the marked exacerbation of this defect during glucagon infusion. The activity of the glucose cycle depends on the rate of phosphorylation of glucose, its polymerization to glycogen, its glycolysis and dephosphorylation in the hexose isomerase reaction: \ glucose-6-phosphate~ fructose-6-phosphate This reaction is considered to be non-rate limiting. The increase in futile cycling in diabetes could be due to a decreased activity of glycogen synthetase or increased activity of glucose-6-phosphatase or both. In alloxandiabetic rats, glucose-6-phosphatase activity is increased [33] [34] [35] , and it is possible that this abnormality could be responsible for increased futile cycling both in diabetic man [13] and in our alloxan-diabetic dogs.
It has also been suggested [36] that the membrane translocase that transports glucose-6-phosphate from the extramicrosomal to the intramicrosomal compartment could be important in metabolic regulation. Thus, there could be a failure to appropriately recognize hyperglycaemia in diabetes, leading to increased activity of glucose-6-phosphatase which could, in turn, augment activity of the glucose cycle.
During the infusion of somatostatin alone, there was a slight though significant decrease in free fatty acids. Restoring insulin to previous basal levels in the alloxandiabetic animals in the present study did not enhance the effectiveness of glucagon suppression by further decreasing FFA levels. What was somewhat unexpected was the doubling in FFA levels in response to selective glucagon excess. Thus, glucagon appears to exert a lipolyric effect in hypoinsulinaemic alloxan-diabetic dogs. Glucagon has been shown to exert a lipolytic effect in isolated rat fat pads, but did not appear to have any effect on human adipocytes [37] . However, it has been shown recently that glucagon was lipolytic in perifused human adipocytes [38] . Glucagon has also been shown to decrease rather than increase FFA in normal dogs [39] . This could be due to stimulation of insulin release, both directly [40] and indirectly, through glucagon-induced hyperglycaemia. The marked increase in FFA in our study suggests that when insulin is subbasal, glucagon becomes a potent stimulator of lipolysis, as has been shown by other investigators [41] . It is possible that glucagon was lipolytic in the isolated adipocytes [38] because they too were in a hypoinsulinaemic environment. This has implications in the development of diabetic ketoacidosis; as insulin levels fall, glucagon rises, which can lead to excess production of FFA and ketone bodies [42] .
The concept that glucagon is lipolytic in diabetes is further strengthened by studies in totally depancreatized insulin-deprived dogs, where somatostatin-induced glucagon suppression resulted in a significant decrease in FFA (unpublished observations). However, in similar studies [4] somatostatin had no effect on tracerdetermined glucose kinetics, suggesting that under conditions of severe chronic insulin deficiency, glucagon suppression was ineffective in improving carbohydrate metabolism. It also suggests that the effects of glucagon suppression on glucose metabolism can be dissociated from the effects on fat metabolism.
In conclusion, the present study demonstrates that (a) futile cycling is increased in alloxan-diabetic dogs, which provide an experimental model for diabetes; (b) glucagon suppression can decrease futile cycling in these diabetic animals, and this effect is intensified if the subnormal basal insulin levels in these animals are prevented from falling further; (c) both exogenous and endogenous hyperglucagonaemia can increase futile cycling; (d) this effect is less pronounced when insulin levels are normal (endogenous hyperglucagonaemia); (e) insulin deficiency appears to exaggerate glucagon's stimulatory effect on futile cycling; and (0 glucagon appears to be fipolytic under conditions of hypoinsulinaemia.
We feel that the data do not permit us to make firm conclusions with respect to the clinical implications of this study. However, we would like to postulate that in postabsorptive diabetes, as in our alloxan-diabetic dogs, futile or substrate cycling may increase to a greater extent than hepatic glucose production in response to stimuli such as hyperglucagonaemia. This could serve to protect hepatic glycogen stores by redirecting some glucose back into the liver, thus tending to ameliorate hyperglycaemia.
